Palisade Bio (PALI) Other Non Operating Income (2014 - 2026)
Palisade Bio's (PALI) quarterly Other Non Operating Income came in at $1.1 million in Q1 2026, up 1318.52% year-on-year from $81000.0 in Q1 2025, and up 6.0% on a QoQ basis from $1.1 million in Q4 2025.
Palisade Bio (PALI) Other Non Operating Income (2014 - 2026) Analysis & Trends
Palisade Bio (PALI) has 13 years of Other Non Operating Income data on file, last reported at $1.1 million in Q1 2026.
- On a quarterly basis, Other Non Operating Income rose 1318.52% year-over-year to $1.1 million in Q1 2026; TTM through Mar 2026 was $2.4 million, a 541.14% increase from a year earlier, with the FY2025 full-year figure at $1.3 million, up 196.77% from the prior year.
- Other Non Operating Income for Q1 2026 stood at $1.1 million, up from $1.1 million in the prior quarter.
- Over the last five years, Other Non Operating Income for PALI reached as high as $1.2 million in Q2 2022 and fell as low as $41000.0 in Q4 2024.
- Historically, Other Non Operating Income has averaged $366823.5 across 5 years, with a median of $187000.0 in 2023.
- Across the five-year window, Other Non Operating Income plunged 99.42% in 2022 and surged 2543.9% in 2025, its largest moves.
- Year by year, Other Non Operating Income stood at $131000.0 in 2022, then surged by 42.75% to $187000.0 in 2023, then plunged by 78.07% to $41000.0 in 2024, then jumped by 2543.9% to $1.1 million in 2025, then rose by 6.0% to $1.1 million in 2026.
- Per Business Quant data, the three most recent Other Non Operating Income figures were $1.1 million in Q1 2026, $1.1 million in Q4 2025, and $59000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,734.26 Bn | 65,733.97 Bn | - |
| 2 | Nanobiotix | 1,919.96 Bn | 1,919.90 Bn | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - |
| 4 | BeOne Medicines | 470.76 Bn | 465.97 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.29 Bn | 115.04 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.97 Bn | 61.22 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.06 Bn | 62.06 Bn | - |
| 8 | Argenx Se | 55.72 Bn | 50.53 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.50 Bn | 34.49 Bn | 959.66 Mn |
| 10 | Palisade Bio | 418.28 Mn | 285.65 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.15 Mn |
| Dec 31, 2025 | 1.08 Mn |
| Sep 30, 2025 | 59,000.00 |
| Jun 30, 2025 | 61,000.00 |
| Mar 31, 2025 | 81,000.00 |
| Dec 31, 2024 | 41,000.00 |
| Sep 30, 2024 | 112,000.00 |
| Jun 30, 2024 | 133,000.00 |
| Mar 31, 2024 | 147,000.00 |
| Dec 31, 2023 | 187,000.00 |
| Sep 30, 2023 | 190,000.00 |
| Jun 30, 2023 | 219,000.00 |
| Mar 31, 2023 | 189,000.00 |
| Dec 31, 2022 | 131,000.00 |
| Sep 30, 2022 | 426,000.00 |
| Jun 30, 2022 | 1.23 Mn |
| Mar 31, 2022 | 794,000.00 |
| Dec 31, 2021 | 22.75 Mn |
| Sep 30, 2021 | 20,000.00 |
| Jun 30, 2021 | 5.13 Mn |